Hotspots and frontiers in pulmonary arterial hypertension research: a bibliometric and visualization analysis from 2011 to 2020

References

• Hoeper MM, McLaughlin VV, Dalaan AM, et al. Treatment of pulmonary hypertension. Lancet Respir Med. 2016 Apr;4(4):323–336.
   PubMed Web of Science ®Google Scholar
• Rubin LJ. Primary pulmonary hypertension. N Engl J Med. 1997 Jan 9; 336(2):111–117.
   PubMed Web of Science ®Google Scholar
• Rubin LJ, Galiè N. Pulmonary arterial hypertension: a look to the future. J Am Coll Cardiol. 2004 Jun 16; 43(12 Suppl S):89s–90s.
   PubMed Web of Science ®Google Scholar
• Li D, Shao NY, Moonen JR, et al. ALDH1A3 coordinates metabolism with gene regulation in pulmonary arterial hypertension. Circulation. 2021 May 25 143(21):2074–2090.
   PubMed Web of Science ®Google Scholar
• Chaumais MC, Djessas MRA, Thuillet R, et al. Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension. Cardiovasc Res. 2021 Apr 23 117(5):1391–1401.
   PubMed Web of Science ®Google Scholar
• Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013 Dec 24 62(25 Suppl):D34–41.
   PubMed Web of Science ®Google Scholar
• Galiè N, Humbert M, Vachiery JL, et al. ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2015 [2016 Jan 1];37(1):67–119.
   PubMed Web of Science ®Google Scholar
• Lau EMT, Giannoulatou E, Celermajer DS, et al. Epidemiology and treatment of pulmonary arterial hypertension. Nat Rev Cardiol. 2017 Oct;14(10):603–614.
   PubMed Web of Science ®Google Scholar
• D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991 Sep 1 115(5):343–349.
   PubMed Web of Science ®Google Scholar
• Chen C. Science mapping: a systematic review of the literature. J Data Inf Sci. 2017 May;2(2):1–40.
   Google Scholar
• Chen C, and Song M. Visualizing a field of research: a methodology of systematic scientometric reviews. Plos One. 2019;14(10):e0223994.
   PubMed Web of Science ®Google Scholar
• Li T, Yang A, Liu G, et al. Status Quo and research trends of craniopharyngioma research: a 10-Year bibliometric analyses (from 2011 to 2020). Front Oncol. 2021;11:744308.
   PubMed Web of Science ®Google Scholar
• Xu G, Jin B, Xian X, et al. Evolutions in the management of hepatocellular carcinoma over last 4 decades: an analysis from the 100 most influential articles in the field. Liver Cancer. 2021 Apr;10(2):137–150.
   PubMed Web of Science ®Google Scholar
• Nabgan W, Jalil AA, Nabgan B, et al. A state of the art overview of carbon-based composites applications for detecting and eliminating pharmaceuticals containing wastewater. Chemosphere. 2021 Oct 11 288(Pt 2):132535.
   PubMedGoogle Scholar
• Aria M, Cuccurullo C. bibliometrix: an R-tool for comprehensive science mapping analysis [Article]. J Informetr. 2017 Nov;11(4):959–975.
   Web of Science ®Google Scholar
• Chen C. Searching for intellectual turning points: progressive knowledge domain visualization. Proc Natl Acad Sci U S A. 2004 Apr 6; 101(Suppl 1(Suppl 1)):5303–5310.
   PubMedGoogle Scholar
• van Eck NJ, Waltman L. Citation-based clustering of publications using CitNetExplorer and VOSviewer. Scientometrics. 2017;111(2):1053–1070.
   PubMed Web of Science ®Google Scholar
• Qin Y, Zhang Q, Liu Y. Analysis of knowledge bases and research focuses of cerebral ischemia-reperfusion from the perspective of mapping knowledge domain. Brain Res Bull. 2020 Mar;156:15–24.
   PubMed Web of Science ®Google Scholar
• Wang C, Jing H, Sun Z, et al. A bibliometric analysis of primary aldosteronism research from 2000 to 2020. Front Endocrinol (Lausanne). 2021;12:665912.
   PubMed Web of Science ®Google Scholar
• Zolty R. Pulmonary arterial hypertension specific therapy: the old and the new. Pharmacol Ther. 2020 Oct;214:107576.
   PubMed Web of Science ®Google Scholar
• Soteriades ES, Falagas ME. Comparison of amount of biomedical research originating from the European union and the United States. Bmj. 2005 Jul 23; 331(7510):192–194.
   PubMedGoogle Scholar
• Thenappan T, Ormiston ML, Ryan JJ, et al. Pulmonary arterial hypertension: pathogenesis and clinical management. Bmj. 2018 Mar 14;360:j5492.
   PubMedGoogle Scholar
• UNESCO [Internet]. Paris; [cited 2021July 11]. Available from: https://www.unesco.org/reports/science/2021/en
   Google Scholar
• Gal D, Glänzel W, Sipido KR. Mapping cross-border collaboration and communication in cardiovascular research from 1992 to 2012. Eur Heart J. 2017 Apr 21; 38(16):1249–1258.
   PubMed Web of Science ®Google Scholar
• Oelrich B, Peters R, Jung K. A bibliometric evaluation of publications in urological journals among European Union countries between 2000-2005. Eur Urol. 2007 Oct;52(4):1238–1248.
   PubMed Web of Science ®Google Scholar
• Garfield E. Journal impact factor: a brief review. Cmaj. 1999 Oct 19;161(8):979–980.
   PubMed Web of Science ®Google Scholar
• Ma C, Su H, Li H. Global research trends on prostate diseases and erectile dysfunction: a bibliometric and visualized study. Front Oncol. 2020;10:627891.
   PubMed Web of Science ®Google Scholar
• Torres F, Rubin LJ. Treprostinil for the treatment of pulmonary arterial hypertension. Expert Rev Cardiovasc Ther. 2013 Jan;11(1):13–25.
   PubMedGoogle Scholar
• Montani D, Chaumais MC, Guignabert C, et al. Targeted therapies in pulmonary arterial hypertension. Pharmacol Ther. 2014 Feb;141(2):172–191.
   PubMed Web of Science ®Google Scholar
• Tuder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med. 1999 Jun;159(6):1925–1932.
   PubMed Web of Science ®Google Scholar
• Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002 Mar 15 165(6):800–804.
   PubMed Web of Science ®Google Scholar
• Sadushi-Koliçi R, Skoro-Sajer N, Zimmer D, et al. Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension. J Heart Lung Transplant. 2012 Jul;31(7):735–743.
   PubMed Web of Science ®Google Scholar
• Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988 Mar 31 332(6163):411–415.
   PubMed Web of Science ®Google Scholar
• Taylor DS, Cheng X, Pawlowski JE, et al. Epiregulin is a potent vascular smooth muscle cell-derived mitogen induced by angiotensin II, endothelin-1, and thrombin. Proc Natl Acad Sci U S A. 1999 Feb 16 96(4):1633–1638.
   PubMed Web of Science ®Google Scholar
• Dhaun N, Webb DJ. Endothelins in cardiovascular biology and therapeutics. Nat Rev Cardiol. 2019 Aug;16(8):491–502.
   PubMed Web of Science ®Google Scholar
• Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002 Mar 21 346(12):896–903.
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov. 2006 Aug;5(8):689–702.
   PubMed Web of Science ®Google Scholar
• Boolell M, Allen MJ, Ballard SA, et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res. 1996 Jun;8(2):47–52.
   PubMedGoogle Scholar
• Eardley I, Ellis P, Boolell M, et al. Onset and duration of action of sildenafil for the treatment of erectile dysfunction. Br J Clin Pharmacol. 2002;53(Suppl 1):61s–65s.
   PubMed Web of Science ®Google Scholar
• Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil study group. N Engl J Med. 1998 May 14 338(20):1397–1404.
   PubMed Web of Science ®Google Scholar
• Montorsi F, McDermott TE, Morgan R, et al. Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies. Urology. 1999 May;53(5):1011–1018.
   PubMed Web of Science ®Google Scholar
• Barnes H, Brown Z, Burns A, et al. Phosphodiesterase 5 inhibitors for pulmonary hypertension. Cochrane Database Syst Rev. 2019 Jan 31 1(1):Cd012621.
   PubMedGoogle Scholar
• Morrison K, Ernst R, Hess P, et al. Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function. J Pharmacol Exp Ther. 2010 Oct;335(1):249–255.
   PubMed Web of Science ®Google Scholar
• Kuwano K, Hashino A, Noda K, et al. A long-acting and highly selective prostacyclin receptor agonist prodrug,2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active form,{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid (MRE-269), on rat pulmonary artery. J Pharmacol Exp Ther. 2008 Sep;326(3):691–699.
   PubMed Web of Science ®Google Scholar
• Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015 Dec 24 373(26):2522–2533.
   PubMed Web of Science ®Google Scholar
• Humbert M, Sitbon O, Yaïci A, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J. 2010 Sep;36(3):549–555.
   PubMed Web of Science ®Google Scholar
• Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010 Jul 13 122(2):156–163.
   PubMed Web of Science ®Google Scholar
• Simonneau G, Torbicki A, Hoeper MM, et al. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J. 2012 Oct;40(4):874–880.
   PubMed Web of Science ®Google Scholar
• Lavelle A, Sugrue R, Lawler G, et al. Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension. Eur Respir J. 2009 Sep;34(3):770–771.
   PubMed Web of Science ®Google Scholar